Skip to main content

Abbott Laboratories Value Stock - Dividend - Research Selection

Abbott Laboratories

ISIN: US0028241000, WKN: 850103

Market price date: 17.05.2022
Market price: 114,54 USD

Abbott Laboratories Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2022
Cash flow
Net operating cash flow 10.533.000.000
Capital Expenditures -1.885.000.000
Free cash flow 8.647.999.488
Balance sheet
Total Equity 35.802.000.000
Liabilities & Shareholders equity 74.380.000.000
Income statement
Net income
Eps (diluted) 3,940
Diluted shares outstanding 1.771.230.000
Net sales/revenue

Fundamental ratios calculated on: 17-05-2022

Key figures 17-05-2022
Cash flow
P/C 19,26
P/FC 23,46
Balance sheet
Income statement
Div. Yield1,59%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization202.876.682.240,00 USD
CountryUnited States
IndicesMSCI World Index,Russell 3000,S&P 500
SectorsHealth Care Equipment
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-01-03,10000.0000/4798.0000; 2013-01-02,10000.0000/4798.0000; 2004-05-04,10000.0000/9356.0000; 2004-05-03,10000.0000/9356.0000; 1998-06-02,2.0000/1.0000; 1998-06-01,2.0000/1.0000; 1992-06-02,2.0000/1.0000; 1992-06-01,2.0000/1.0000; 1990-06-02,2.0000/1.0000; 1990-06-01,2.0000/1.0000; 1986-06-03,2.0000/1.0000; 1986-06-02,2.0000/1.0000; 1981-06-01,2.0000/1.0000; 1981-05-30,2.0000/1.0000; 1981-05-29,2.0000/1.0000; 1978-05-23,2.0000/1.0000; 1978-05-22,2.0000/1.0000; 1975-08-26,2.0000/1.0000; 1975-08-25,2.0000/1.0000; 1964-04-28,2.0000/1.0000; 1964-04-27,2.0000/1.0000

Description of the company

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


What's being done to address the baby formula shortage

The U.S. is experiencing a shortage of baby formula. The real turning point came in mid-February, after supply chain constraints were already pressuring the sector.

What happened with Abbott baby formula that worsened a U.S. shortage?

(This story corrects to drop "Dr" title before Peter Pitts' name in paragraph 11)

Baby formula shortage is ‘very surreal’ and ‘not slowing down’: Bobbie CEO

Bobbie Co-Founder and CEO Laura Modi joins Yahoo Finance Live to discuss how her company's organic baby formula is hoping to ease supply concerns and accessibility issues stemming from the baby formula shortage.

Baby formula shortage leads House to introduce bill to address ongoing crisis

Yahoo Finance's Anjalee Khemlani details the legislation Congress is putting forth to address and alleviate the pains families are feeling from the ongoing baby formula shortage, as well as how the FDA is pushing formula production.

A major baby formula manufacturing plant is reopening. But a real solution to the supply shortage is still months away

"We're desperate, we're really desperate," says one mother.

House Democrats introduce bill to address baby formula shortage

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Baby formula: US shortage highlights industry concentration

In the US, this fear has become acute amid a nationwide infant formula shortage. The resulting controversy underlines the position of commercial baby milk as a touchstone for public trust — or the lack of it — in business. Nestlé’s marketing practices triggered boycotts in the 1970s.

TIMELINE-Baby formula crunch in U.S. forces scramble to boost supplies

The nationwide shortage of baby formula has prompted the United States to temporarily allow foreign imports from other suppliers, while reaching a deal with Abbott Laboratories on steps to resume production at its Michigan plant. Top infant formula makers, including Reckitt Benckiser and Nestle, are also ramping up supplies to the country. Abbott recalls dozens of types of powdered baby formulas, including Similac, Alimentum and EleCare, made at its Sturgis, Michigan plant after four consumers complained about bacterial infections in infants who had consumed those products; Recalled products had an expiry date of April 1, 2022 or later.

United Airlines, Abbott rise; Walmart, Fluor fall

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

EXPLAINER: What we know about shuttered baby formula plant

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.